Takeda Posts Sharply Higher Quarterly Profit, Raises Annual Guidance
By Kosaku Narioka
Takeda Pharmaceutical reported sharply higher quarterly net profit and raised its annual earnings guidance.
The Japanese drugmaker said Thursday that net profit more than quadrupled to 103.6 billion yen, equivalent to $675.3 million, for the three months ended December.
That was below the estimate of Y107.9 billion in a poll of analysts by data provider Visible Alpha. For the year-ago period, the company reported net profit of Y23.8 billion, which was partly weighed by restructuring expenses.
Third-quarter revenue grew 4.2% from a year earlier to Y1.192 trillion.
For the fiscal year ending March, it projected revenue to decline 1.1% to Y4.530 trillion and net profit to climb 43% to Y154.00 billion. The company previously forecast revenue of Y4.500 trillion and net profit of Y153.00 billion.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
January 29, 2026 02:11 ET (07:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
10 Best Blue-Chip Stocks to Buy for the Long Term
United States